Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma

Study:

Phase II Study of TKI258 (Dovitinib) in Patients With Recurrent or Progressive Glioblastoma Who Have Progressed on Anti-Angiogenic Therapy (Including Anti-VEGF Therapy)

Rationale:

n/a

Purpose:

This phase II trial studies how well dovitinib works in treating patients with recurrent or progressive glioblastoma. Dovitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth

Study Status: Recruiting

Recruiting:
Manmeet S. Ahluwalia 216-444-6145 ahluwam@ccf.org

Condition Intervention Phase
Adult Giant Cell Glioblastoma
Adult Glioblastoma
Adult Gliosarcoma
Recurrent Adult Brain Tumor		 Drug: dovitinib
Other: laboratory biomarker analysis		 Phase 2

Verified by Manmeet Ahluwalia, MD December, 2012

Sponsored by: Manmeet Ahluwalia, MD
Information provided by: Case Comprehensive Cancer Center
ClinicalTrials.gov identifier: NCT01753713

Study Type: Interventional

Study Design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Cleveland, Ohio 44195
United States

Manmeet Ahluwalia., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.